A

AbbVie

Global biopharmaceutical company developing medicines

Brand Manager - Dry Eye Portfolio

Full-TimeUpdated on 10/23/2026
No salary listed
Mid, Senior
Bachelor's, MBA
Pathum Wan, Thailand
HybridHybrid role in Pathum Wan, Bangkok; domestic and international travel as required.
Growth & MarketingBrand & Creative Marketing

About the job

Requirements
  • A bachelor's degree in Pharmacy, Science, Health Sciences, Business, Marketing, or a related discipline is required; an MBA or relevant postgraduate qualification is an advantage.
  • At least 5 years of pharmaceutical or healthcare industry experience, including at least 3 years in product management, brand management, or a comparable commercial role in a multinational environment.
  • Demonstrated experience supporting or leading product launches, new indications, or major lifecycle initiatives, translating strategy into execution.
  • Experience in Eyecare, specialty care, or hospital-based markets is preferred.
  • Strong knowledge of Thailand's pharmaceutical and healthcare environment.
  • Capability in insight generation, strategic planning, financial management, forecasting, performance analysis, and prioritization.
  • Ability to influence without authority, align diverse stakeholders, manage ambiguity, and deliver through cross-functional teams.
  • Professional fluency in Thai and English.
  • Proficiency in Microsoft Office and comfort using data, omnichannel platforms, content-creation tools, and responsible AI-enabled tools.
  • Willingness to travel domestically and internationally for field engagement, business meetings, and product training as required.
Responsibilities
  • Set the long-term brand ambition and own end-to-end strategy for assigned Eyecare products across launch, growth, maturity, and lifecycle optimization.
  • Translate global and Area strategy into a locally relevant, insight-led annual brand plan with priorities, investment choices, milestones, and success measures.
  • Lead launch excellence for new products, indications, and line extensions, from early market shaping and readiness planning through execution and post-launch optimization.
  • Develop understanding of patients, customers, the treatment pathway, market access dynamics, competitors, and emerging trends; commission market research and convert insights into action.
  • Define differentiated positioning, value propositions, segmentation, targeting, channel strategy, and core messages for priority customer groups.
  • Design and execute integrated, customer-centric omnichannel campaigns that strengthen engagement, support field execution, and maximize brand impact.
  • Identify portfolio, indication, market-development, pricing, packaging, and partnership opportunities for sustainable growth and long-term value.
  • Establish performance dashboards and lead regular business reviews, using indicators to identify risks, optimize investment, and initiate corrective action.
  • Provide senior stakeholders with decision-oriented updates on performance, strategic choices, opportunities, risks, and milestone progress.
  • Build and manage the annual brand budget, allocate resources to high-value opportunities, and control spend.
  • Partner with Finance and Sales to develop sales forecasts, scenario plans, and business cases based on market assumptions and performance drivers.
  • Recommend pricing and pricing-adjustment strategies that balance patient access, competitiveness, revenue growth, and gross-profit objectives.
  • Track investment effectiveness and forecast accuracy, address variances, and reallocate resources as priorities change.
  • Collaborate with Supply Chain and Logistics on demand planning, inventory management, sample availability, and continuity of supply, particularly during launch and growth phases.
  • Partner with Medical Affairs and Area/Global teams so brand strategy reflects robust science, relevant evidence, and evolving standards of care.
  • Build and maintain compliant relationships with key opinion leaders, professional societies, healthcare institutions, and relevant patient or health organizations.
  • Develop local external-engagement and expert-development plans supporting education, scientific exchange, market shaping, and responsible brand growth.
  • Contribute to advisory boards, speaker programs, congresses, and scientific meetings with Medical Affairs and in compliance with applicable requirements.
  • Translate strategy into product, disease-state, customer-engagement, and launch-readiness training for company and distributor field teams.
  • Partner with Sales Force Effectiveness, Training, Medical Affairs, and Sales leadership to identify capability gaps and deliver practical learning that improves execution.
  • Ensure training content is scientifically accurate, customer-relevant, engaging, aligned with approved brand strategy, and compliant.
  • Select and lead external agencies with clear briefs, governance, timelines, quality standards, budgets, and performance indicators.
  • Lead the cross-functional brand team and create shared ownership of priorities, decisions, milestones, and outcomes across relevant functions and partners.
  • Influence without direct authority, constructively challenge assumptions, resolve trade-offs, and maintain momentum in a complex matrix environment.
  • Partner with Regulatory Affairs to prioritize product, indication, and packaging submissions and support approval and launch readiness.
  • Collaborate with Market Access on value creation and appropriate engagement with priority accounts, institutions, and payers.
  • Translate brand strategy into focused field guidance and partner with Sales leadership on goal setting, prioritization, capability needs, and performance tracking.
  • Conduct regular field visits and customer engagement to gain first-hand insights and improve strategy and execution.
  • Ensure marketing, launch, digital, agency, and promotional activities comply with company policies, approval processes, industry codes, and applicable Thai laws and regulations.
  • Embed quality and compliance across planning, execution, documentation, vendor management, safety-monitoring collaboration, and internal audit readiness.
  • Complete required business processes and training on time, including relevant approval, expense, and learning systems.
  • Model company values, ethical decision-making, patient centricity, accountability, and a speak-up culture.
Desired Qualifications
  • Experience in Eyecare, specialty care, or hospital-based markets.
  • An MBA or relevant postgraduate qualification.

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

4%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Oct 24th, 2026
AbbVie wins FDA nod for at-home Skyrizi starts in Crohn's; sales boost seen after 60-90 days

AbbVie won US Food and Drug Administration (FDA) approval on October 23 for an at-home start to Skyrizi in adults with moderately to severely active Crohn's disease. Patients previously had to begin with intravenous infusions; they can now take the first doses at home with an on-body injector. By Week 12, 74% of patients new to advanced therapy reached clinical remission, against 27% on placebo. Johnson & Johnson's rival Tremfya won similar approval about 19 months earlier. Chief commercial officer Jeff Stewart said full paid access "will probably take 60 or 90 days" because insurers must approve the regimen. Sales impact should therefore come mostly after the fourth quarter. AbbVie reports third-quarter results on October 30. It guides for revenue of about $17.2 billion; Skyrizi's franchise sold $17.562 billion in 2025.

Yahoo Finance
Oct 23rd, 2026
ETFs net sell $42.1M of AbbVie as XLV leads $32.0M exit

Exchange-traded funds (ETFs) were net sellers of AbbVie shares for a second straight session, selling a net $42.1 million on October 21. Sellers moved larger sums even though more funds bought than sold: 24 ETFs added shares and 23 cut them. The Health Care Select Sector SPDR Fund led the selling with $32.0 million, followed by iShares Core S&P 500 ETF at $9.3 million and SPDR S&P 500 ETF Trust at $2.0 million. On October 20, ETFs sold a net $6.7 million, after three days of net buying. AbbVie has a market cap of $504.0 billion. Trailing 12-month revenue was $64.39 billion, up 10.3% over the past year.

Yahoo Finance
Oct 22nd, 2026
Abbott stock: $247,767 in shares yields $500 a month in dividends ahead of Q3 earnings

Abbott Laboratories will report third-quarter earnings before the market opens on Wednesday, October 21. Analysts expect earnings of $1.41 per share, up from $1.30 a year earlier, and revenue of $12.99 billion, against $11.37 billion last year. On October 16, TD Cowen analyst Joshua Jennings reiterated a Buy rating and a $135 price target. Abbott pays a quarterly dividend of 63 cents per share ($2.52 a year), a yield of 2.42%. To earn $500 a month ($6,000 a year) from dividends alone, an investor would need about 2,381 shares, or roughly $247,767.

Yahoo Finance
Oct 21st, 2026
Retirees swap Social Security for 5 dividend stocks yielding up to 6.64%

Retirees looking for income beyond Social Security are turning to dividend stocks. The 2027 cost-of-living adjustment is tracking toward 3.3%, and five companies from different industries were screened for dividend safety first, then yield. Verizon yields 6.64% and Altria 6.17%. Verizon's free cash flow guidance of $21.94 billion to $22.14 billion covers its roughly $11.76 billion annual dividend. Altria's payout is about 79% of the low end of its 2026 earnings guidance. Realty Income pays monthly at a 5.99% yield and has raised its dividend 115 consecutive quarters. Enbridge yields 5.95%. AbbVie yields 2.48%, but its quarterly dividend has grown from $0.40 in 2013 to $1.73 in 2026. Risks include satellite competition for Verizon, falling cigarette volumes for Altria, and currency swings for Enbridge.

Yahoo Finance
Oct 19th, 2026
Merck and AbbVie shares jump 39% and 24% in 2026 as dividend picks for a decade

Healthcare stocks are rebounding in 2026, led by Merck and AbbVie. Merck shares have climbed 39% and AbbVie's 24%, against about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating Wall Street estimates. Keytruda sales hit $8.4 billion, though the drug will likely lose patent exclusivity by 2028. A subcutaneous version, Keytruda Qlex, may help retain market share. Merck's forward dividend yield is 2.3%. AbbVie's revenue grew 10.2% to almost $17 billion, with adjusted earnings per share up 22.9% to $3.65. Skyrizi and Rinvoq sales each rose about 24%, and neither faces US competition until 2033 and 2037 respectively. AbbVie has raised its dividend for 54 straight years, including its time as part of Abbott Laboratories.